Abstract: The present disclosure provides methods and compositions for the detection of bladder in a subject using four locus-specific probes to 6p22, 8q22, 11q13, and 20p11.2.
Type:
Grant
Filed:
January 30, 2019
Date of Patent:
October 24, 2023
Assignee:
Board of Regents, The University of Texas System
Inventors:
Bogdan Czerniak, Keith Baggerly, Jolanta Bondaruk, Tadeusz Majewski, Colin Dinney, Shizhen Zhang, Yan Wang
Abstract: Provided herein is technology relating to predicting a subject's resistance or responsiveness to a decitabine based therapy and particularly, but not exclusively, to methods, compositions, and related uses for predicting a subject's resistance or responsiveness to a decitabine based therapy wherein the subject is diagnosed with chronic myelomonocytic leukemia.
Type:
Grant
Filed:
February 11, 2021
Date of Patent:
October 24, 2023
Assignee:
The Regents of the University of Michigan
Inventors:
Maria Figueroa, Kristen M. Plasseraud, Tingting Qin, Valeria Santini
Abstract: The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on the determined prognosis of the subject.
Abstract: In one aspect provided herein are methods of determining a triple negative breast cancer (TNBC) subtype in an individual in need thereof comprising determining expression of one or more genes in one or more TNBC cells of the individual; and comparing the expression of the one or more genes in the TNBC cells with the expression of the one or more genes in a control. In another aspect, the methods are directed to determining a treatment protocol for the TNBC patient based on the TNBC subtype. In another aspect, the methods are directed to predicting whether an individual will benefit from a treatment for a particular TNBC subtype. In yet another aspect, the invention is directed to a method of determining whether an agent can be used to treat a TNBC subtype.
Type:
Grant
Filed:
January 17, 2020
Date of Patent:
October 17, 2023
Assignee:
Vanderbilt University
Inventors:
Jennifer A. Pietenpol, Brian Lehmann, Josh Bauer, Xi Chen
Abstract: Disclosed herein is a method to isolate and cultivate the lung microbiome obtained from bronchoalveolar lavage. The disclosed method involves lung microbiome culturomics based on three different media for both aerobic and fastidious anaerobic bacteria. The disclosed method allows for amplification of the lung microbiome, which can be used, for example, for subsequent testing of antibiotic sensitivity, drug resistance, or for lung microbiome transplantation.
Abstract: The present invention provides for the first time the identification of salivary protein and RNA factors that can be used in the detection of diabetes. The present invention therefore provides methods of diagnosing and providing a prognosis for diabetes, by examining relevant proteins and RNA in a patient's saliva.
Type:
Grant
Filed:
October 24, 2014
Date of Patent:
October 3, 2023
Assignee:
The Regents of the University of California
Abstract: The invention provides compositions, methods, and systems for using cell-free RNA for improved detection of rare cells and/or species that are useful for diagnosing and/or monitoring cancer. The invention also provides for compositions, methods, and systems for early detection of cells that are resistant and/or developing resistance to cancer therapies.
Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
September 26, 2023
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention relates to a method for rapidly detecting copies of at least one RNA molecule expressed in individual cells and uses thereof.
Type:
Grant
Filed:
January 8, 2021
Date of Patent:
September 26, 2023
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Yuri Bushkin, Maria L. Gennaro, Sanjay Tyagi, Richard Pine
Abstract: The invention aims at a non-invasive method of early diagnosis of gastric cancer, using as a biomarker the levels of methylation of the DNA sequence of the promoter of the Reprimo-like gene in plasma. The inventors have established the utility of Reprimo-like as a biomarker, and especially as a biomarker for the early detection of gastric cancer, since they have determined that Reprimo-like is consistently silenced in gastric cancer, both in incipient and advanced stages. This silencing is given by methylation of its promoter region, which is detectable in plasma samples, allowing us to measure it as a liquid biopsy in a non-invasive, fast and inexpensive way.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
September 5, 2023
Assignee:
Pontificia Universidad Catolica de Chile
Abstract: The disclosure provides methods and compositions, e.g., kits, for identifying or authenticating a sample, e.g., a tumor model, based on the genotype of the sample at a group of SNP loci.
Type:
Grant
Filed:
May 25, 2021
Date of Patent:
August 29, 2023
Assignee:
CROWN BIOSCIENCE (SUZHOU) INC.
Inventors:
Sheng Guo, Xiaobo Chen, Wubin Qian, Henry Li
Abstract: Methods and compositions are provided for determining whether an adenocarcinoma or squamous cell carcinoma patient is likely to respond to PARP inhibitor treatment. Specifically, a method of assessing whether a patient's adenocarcinoma (AD) lung cancer subtype is terminal respiratory unit (TRU), proximal inflammatory (PI), or proximal proliferative (PP) or a patient's squamous cell carcinoma (SQ) is primitive, classical, secretory or basal is provided herein. The method entails detecting the levels of classifier biomarkers at the nucleic acid level, in an AD or SQ lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the AD lung cancer sample is classified as a TRU, PI, or PP AD sample or the SQ lung cancer sample is classified as primitive, classical, secretory or basal and a determination of whether the patient is likely to respond to PARP inhibitor treatment can be made.
Type:
Grant
Filed:
July 20, 2018
Date of Patent:
August 29, 2023
Assignees:
GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
Inventors:
Myla Lai-Goldman, Hawazin Faruki, Greg Mayhew, Charles Perou, David Neil Hayes
Abstract: The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that proposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF), secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis, a secondary MDS or an AML.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
August 22, 2023
Assignee:
Institut Gustave-Roussy
Inventors:
Christine Bellane-Chantelot, Isabelle Plo, William Vainchenker, Cécile Saint-Martin, Antonio D Di Stefano, Joseph Saliba
Abstract: Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.
Type:
Grant
Filed:
September 3, 2020
Date of Patent:
August 22, 2023
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Carl M. Gay, Lauren A. Byers, John V. Heymach
Abstract: Provided are a detection kit and detection method for ITGA4 gene methylation. A primer and a probe provided by the present invention are matched, then detection can be carried out by taking a feces sample as an object, and thus the detection is simple, convenient and rapid. The detection can also be carried out on tissue specimens. Moreover, in the process of detecting the samples, the detection specificity and sensitivity are also improved. The experiment proves that for the feces specimen, when the specificity is 95.2%, the sensitivities of the methylated ITGA4 to intestinal cancer and adenoid tumor are 83.8% and 41.6%, respectively; and for the intestinal cancer tissue, when the specificity is 97.6% (40/41), the detection rates for colorectal cancer and adenoid tumor are 96.2% (101/105) and 71.6% (78/109), respectively. The effects are superior to the detection effects obtained by adopting other primers or probes.
Abstract: Provided is a method of diagnosing lymphoma by analyzing an increase or decrease in contents of specific bacterial extracellular vesicles by performing bacterial metagenomic analysis using normal individual and subject-derived samples, wherein a lymphoma risk group may be diagnosed and predicted early to delay the time of onset or prevent the onset of lymphoma with proper cure, and after onset, early diagnosis may be performed, thereby reducing the incidence of lymphoma and increasing a therapeutic effect.
Abstract: Provided herein is technology for prostate cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of prostate cancer.
Type:
Grant
Filed:
January 8, 2021
Date of Patent:
July 11, 2023
Assignees:
Mayo Foundation for Medical Education and Research, Exact Sciences Corporation
Inventors:
David A. Ahlquist, William R. Taylor, John B. Kisiel, Tracy C. Yab, Douglas W. Mahoney, Brian A. Dukek, Matthew T. Gettman, Hatim T. Allawi
Abstract: Disclosed is an adaptor for sequencing DNAs at ultratrace levels and its uses. The adaptor contains, from 5?terminus to 3?terminus, a Tag sequence, PolyNs, a first stem sequencing, a first loop sequence, dUTP(s), a second loop sequence, and a second stem sequence, wherein the second stem sequence is complementary to the first stem sequence when read in opposite directions, and the 5?terminus of the adaptor is phosphorylated. The adaptor is designed to form a hairpin structure itself in use and then ligated to a DNA molecule of interest, so that adaptor-adaptor ligation can be effectively avoided, eliminating the inefficient adaptor-DNA ligation problem. Such an adaptor is especially suitable for library construction and sequencing of DNAs at ultratrace levels, laying a good basis for accurate sequencing of ctDNAs.
Type:
Grant
Filed:
May 27, 2017
Date of Patent:
June 13, 2023
Inventors:
Xiaoni Zhang, Ming Liu, Guolin Zhong, Mingyan Xu
Abstract: The present application mainly relates to a method for determining a prognosis for a subject diagnosed with high-grade serous ovarian cancer. The method comprises determining the prognosis based on activities of at least two cellular signaling pathways including a phosphatidylinositide 3-kinase (PI3K) pathway and a nuclear factor-kappa B (NFkB or NF?B) pathway in a sample of the subject. The present application also relates to a method for identifying a subject diagnosed with high-grade serous ovarian cancer that will be suitable for a PI3K pathway targeting therapy or an NFkB pathway targeting therapy. The method comprises identifying the subject based on activities of at least two cellular signaling pathways including a PI3K pathway and an NFkB pathway in a sample of the subject. The present application further relates to corresponding apparatuses, non-transitory storage media, computer programs and kits.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
June 13, 2023
Assignee:
KONINKLIJKE PHILIPS N.V.
Inventors:
Anja Van de Stolpe, Wilhelmus Franciscus Johannes Verhaegh